Overview

Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-10
Target enrollment:
Participant gender:
Summary
Tislelizumab in resectable esophageal squamous cell carcinoma
Phase:
PHASE2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
tislelizumab